Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-336717
Filing Date
2026-08-06
Accepted
2026-08-06 07:10:58
Documents
56
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cgem-20260630.htm   iXBRL 10-Q 1954529
2 EX-31.1 cgem-ex31_1.htm EX-31.1 15719
3 EX-31.2 cgem-ex31_2.htm EX-31.2 15495
4 EX-32.1 cgem-ex32_1.htm EX-32.1 14531
  Complete submission text file 0001193125-26-336717.txt   8220325

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20260630.xsd EX-101.SCH 1149495
60 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20260630_htm.xml XML 1636174
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 261245948
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)